Press Releases Year None202320222021202020192018 Jun 23, 2023 Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology Jun 05, 2023 Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease Jun 01, 2023 Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1 May 31, 2023 Akero Therapeutics to Present at the Jefferies Healthcare Conference May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH Mar 17, 2023 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Jan 10, 2023 Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy Jan 04, 2023 Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 20 of 20
Year None202320222021202020192018 Jun 23, 2023 Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology Jun 05, 2023 Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease Jun 01, 2023 Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1 May 31, 2023 Akero Therapeutics to Present at the Jefferies Healthcare Conference May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH Mar 17, 2023 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Jan 10, 2023 Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy Jan 04, 2023 Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 20 of 20
Jun 23, 2023 Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Jun 05, 2023 Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Jun 01, 2023 Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
May 16, 2023 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 15, 2023 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Mar 29, 2023 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
